|
Tuesday, March 25 7:00am
Registration (Open until 5:30pm)
8:00 Plenary Keynote Introduction
 Harry Glorikian, Managing Partner, Scientia Advisors 8:15 Diagnosing the Disease: Disruptive Innovation in Healthcare
 Clayton M. Christensen, DBA, Robert and Jane Cizik Professor of Business Administration, Harvard Business School 9:45 Coffee Break 10:15am 丒1:15pm Morning Pre-Conference Short Courses*
Recommended Morning Short Courses* |
(SC2) THE CHALLENGE OF THE BLOOD-BRAIN BARRIER 丒A MEDICINAL CHEMISTRY PERSPECTIVE
-
The In's and Out's of Blood-brain Transport: Blood-brain Barrier Physiology and
Transport Methodologies
Claude Dagenais, B.Pharm., Ph.D. Senior Scientist, Neuroscience Department, Amgen Inc.
-
The Challenge of the Blood-brain Barrier
Douglas K. Spracklin, Ph.D., Director, Biotransformation & Enzymology, Pfizer Inc.
-
Application of Pharmacokinetic/Pharmacodynamic Modeling to Centrally Targeted Agents
Ellen Q. Wang, Ph.D., Senior Principal Scientist, Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development
-
Blood-brain Barrier Models
Romeo Cecchelli, Ph.D., Vice President, University of Artois; Head, BBB Laboratory; Scientific Advisor, Cellial Technologies
(SC3) ADMET CASE STUDIES FROM A MEDICINAL CHEMISTRY PERSPECTIVE
-
In Vitro ADME Assays: Strategic Application to Drug Discovery
Dhiren R. Thakker, Ph.D., Ferguson Distinguished Professor and Associate Dean, Research and Graduate Education, School of Pharmacy, UNC-Chapel Hill
-
Solubility, Data Integration,
in Vitro/in Vivo Correlations
Philip S. Burton, Ph.D., Chief Executive & Scientific Officer, ADMETRx, Inc.
-
In Vitro Toxicity Assays That Have
in Vivo Relevance
James McKim, Ph.D., DABT, President & Chief Scientific Officer, CeeTox, Inc.
-
Case Study: Impact of Structure and Physchem Properties on Oral Delivery of
Antivirals
Gail L Strong, Ph.D., Director, Pharmaceutical Sciences, Theravance, Inc.
2:30 - 5:30 Afternoon Pre-Conference Short Course* |
Recommended Afternoon Short Course* |
|
(SC8) MODELS FOR EVALUATING DRUG-DRUG INTERACTION POTENTIAL IN PRECLINICAL DEVELOPMENT
-
From Benchtop to Regulatory Guidance: Effective Strategies to Identify Drug-Drug
Interaction (DDI) Liability
Joseph Ware, Ph.D., Senior Scientist, Late Stage PK/PD, Genentech, Inc.
-
In Vitro Models of CYP Inhibition and Induction
James McKim, Ph.D., DABT, President & Chief Scientific Officer, CeeTox, Inc.
-
In Vitro Drug Transporter Models
Philip S. Burton, Ph.D., Chief Executive & Scientific Officer, ADMETRx, Inc.
* Separate Registration Required |
|
Japanese
Korean
English